Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;6(3):349-62.
doi: 10.2217/bmm.12.19.

Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Daniel Crona  1 , Federico Innocenti
Affiliations
Review

Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Daniel Crona et al. Biomark Med. 2012 Jun.

Abstract

The systemic treatment of cancer with traditional cytotoxic chemotherapeutic agents and more targeted agents is often complicated by the onset of adverse drug reactions. Pharmacogenetic prediction of adverse drug reactions might have consequences for dosing and efficacy. This review discusses relevant examples where the germline variant-toxicity relationship has been validated as an initial step in developing clinically useful pharmacogenetic markers and provides examples where germline variants have influenced dosing strategies and/or survival or other outcomes of efficacy. This review will also provide insight into the reasons why more pharmacogenetic markers have not been routinely integrated into clinical practice.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Hoskins JM, Carey LA, Mcleod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576–586. - PubMed
    1. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429(6990):464–468. - PubMed
    1. Evans WE, Mcleod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538–549. - PubMed
    1. Sassi G, Striano B, Merlo UA. A reporting system for the assessment of chemotherapy toxicity. J Oncol Pharm Pract. 2005;11(2):63–67. - PubMed
    1. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in Phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708–720. - PMC - PubMed

Websites

    1. National Cancer Institute. Cancer Therapy Evaluation Program NCI. Common Terminology Criteria for Adverse Events (CTCAE) v.4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-2006-14_QuickReference....
    1. US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labels. www.fda.gov/drugs/scienceresearch/researchareas/Pharmacogenetics/ucm0833....
    1. Pharmacogenomics Research Network. www.pgrn.org.
    1. Pharmacogenomics The Knowledgebase. www.pharmgkb.org.
    1. Pharmacogenomics for Every Nation Initiative. www.pgeni.org.

Publication types

Substances